Preclinical efficacy studies validate Myricx Bio’s proprietary N-Myristoyltransferase inhibitor (NMTi) payload platformComplete tumour regressions across a range of solid tumour xenograft models for NMTi-ADCs targeting three clinically validated tumour-associated antigens (B7-H3, TROP2 and HER2)Encouraging initial non-human primate tolerability data presentedData presentation at the 14th Annual World ADC Conference in San Diego LONDON, Oct.

临床前疗效研究验证了Myricx Bio专有的N-肉豆蔻酰转移酶抑制剂（NMTi）有效载荷平台在NMTi ADC的一系列实体瘤异种移植模型中完成肿瘤消退，靶向三种临床验证的肿瘤相关抗原（B7-H3，TROP2和HER2），鼓励最初的非人类灵长类动物耐受性数据在第14届年度提交数据世界ADC会议在圣地亚哥-伦敦，10月。

17, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is presenting preclinical in vivo efficacy data for its NMTi-ADC platform and pipeline at the 14th Annual World ADC Event, San Diego, California, held from October 16-19, 20231.

172023（GLOBE NEWSWIRE）-Myricx Bio（'Myricx'），一家英国生物技术公司，专注于发现和开发一类全新的抗体-药物偶联物（ADC）有效载荷，目前正在提供临床前体内疗效其NMTi ADC平台和管道的数据于20231年10月16日至19日举行的第14届年度世界ADC活动，加利福尼亚州圣地亚哥。

Myricx’s payload platform is based on proprietary potent small molecule NMT inhibitors (NMTi). In the poster presentation Myricx reported data for three NMTi-ADCs in its pipeline. These comprise B7-H3-NMTi, TROP2-NMTi, and HER2-NMTi. B7-H3-NMTi demonstrated complete and durable tumour regressions in multiple models of aggressive prostate cancer refractory to Topo1i-based ADCs.

Myricx的有效载荷平台基于专有的强效小分子NMT抑制剂（NMTi）。在海报展示中，Myricx报告了其管道中三个NMTi ADC的数据。这些包括B7-H3-NMTi，TROP2-NMTi和HER2-NMTi。B7-H3-NMTi在基于Topo1i的ADC难治的侵袭性前列腺癌的多种模型中表现出完全且持久的肿瘤消退。

Initial toxicology is currently under evaluation in non-human primates. TROP2-NMTi also demonstrated complete and durable tumour regressions in breast cancer models refractory to Topo1i-based ADCs; including the ability to regress large and established tumours that had prior exposure to a Topo1i-based ADC.

最初的毒理学目前正在非人类灵长类动物中进行评估。TROP2-NMTi还在基于Topo1i的ADC难以治疗的乳腺癌模型中显示出完全持久的肿瘤消退；包括能够回归先前暴露于基于Topo1i的ADC的大型已建立肿瘤的能力。

HER2-NMTi demonstrated complete efficacy, and an encouraging tolerability profile in rodents and non-human primates. In addition, it showed potent bystander activity, and efficacy in patient-derived xenograft (PDX) organoid models with a broad range of antigen expression levels. Myricx CEO, Dr .

HER2 NMTi在啮齿动物和非人灵长类动物中表现出完全功效和令人鼓舞的耐受性特征。此外，它在具有广泛抗原表达水平的患者衍生的异种移植物（PDX）类器官模型中显示出有效的旁观者活性和功效。Myricx首席执行官博士。